140 related articles for article (PubMed ID: 22943879)
21. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
Prince HM; Rischin D; Quinn M; Allen D; Planner R; Neesham D; Gates P; Davison J
Gynecol Oncol; 2001 May; 81(2):216-24. PubMed ID: 11330952
[TBL] [Abstract][Full Text] [Related]
22. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.
Tiersten AD; Liu PY; Smith HO; Wilczynski SP; Robinson WR; Markman M; Alberts DS
Gynecol Oncol; 2009 Mar; 112(3):444-9. PubMed ID: 19138791
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer.
Taylor SE; Petschauer JS; Donovan H; Schorzman A; Razo J; Zamboni WC; Edwards RP; Zorn KK
Int J Gynecol Cancer; 2019 Jan; 29(1):147-152. PubMed ID: 30640697
[TBL] [Abstract][Full Text] [Related]
24. Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
Arimoto T; Nakagawa S; Oda K; Kawana K; Yasugi T; Taketani Y
Med Oncol; 2012 Jun; 29(2):1253-4. PubMed ID: 21380784
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H
Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876
[TBL] [Abstract][Full Text] [Related]
27. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
Micha JP; Goldstein BH; Rettenmaier MA; Mattison J; Graham C; Birk CL; Brown JV
Gynecol Oncol; 2004 Sep; 94(3):719-24. PubMed ID: 15350364
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial.
Markman M; Glass T; Smith HO; Hatch KD; Weiss GR; Taylor SA; Goodwin JW; Alberts DS
Gynecol Oncol; 2003 Mar; 88(3):282-8. PubMed ID: 12648576
[TBL] [Abstract][Full Text] [Related]
29. Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Look KY; Bookman MA; Schol J; Herzog TJ; Rocereto T; Vinters J;
Gynecol Oncol; 2004 Jan; 92(1):93-100. PubMed ID: 14751144
[TBL] [Abstract][Full Text] [Related]
30. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.
Hsu Y; Sood AK; Sorosky JI
Am J Clin Oncol; 2004 Feb; 27(1):14-8. PubMed ID: 14758127
[TBL] [Abstract][Full Text] [Related]
31. Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
Schlappe BA; Mueller JJ; Zivanovic O; Gardner GJ; Long Roche K; Sonoda Y; Chi DS; O'Cearbhaill RE
Gynecol Oncol; 2016 Jul; 142(1):13-18. PubMed ID: 27189456
[TBL] [Abstract][Full Text] [Related]
32. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
33. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
34. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Walker JL; Brady MF; Wenzel L; Fleming GF; Huang HQ; DiSilvestro PA; Fujiwara K; Alberts DS; Zheng W; Tewari KS; Cohn DE; Powell MA; Van Le L; Davidson SA; Gray HJ; Rose PG; Aghajanian C; Myers T; Alvarez Secord A; Rubin SC; Mannel RS
J Clin Oncol; 2019 Jun; 37(16):1380-1390. PubMed ID: 31002578
[TBL] [Abstract][Full Text] [Related]
35. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Hook J; Coyle C; Blagden S; Brenton JD; Naik R; Perren T; Sundar S; Cook AD; Gopalakrishnan GS; Gabra H; Lord R; Dark G; Earl HM; Hall M; Banerjee S; Glasspool RM; Jones R; Williams S; Swart AM; Stenning S; Parmar M; Kaplan R; Ledermann JA
Lancet; 2019 Dec; 394(10214):2084-2095. PubMed ID: 31791688
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer.
Micha JP; Goldstein BH; Rettenmaier MA; Genesen M; Graham C; Bader K; Lopez KL; Nickle M; Brown JV
Int J Gynecol Cancer; 2007; 17(4):771-6. PubMed ID: 17343605
[TBL] [Abstract][Full Text] [Related]
37. SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer.
Vasey PA; Atkinson R; Osborne R; Parkin D; Symonds R; Paul J; Lewsley L; Coleman R; Reed NS; Kaye S; Rustin GJ
Br J Cancer; 2006 Jan; 94(1):62-8. PubMed ID: 16404361
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.
Landrum LM; Hyde J; Mannel RS; McMeekin DS; Moore KN; Walker JL
Gynecol Oncol; 2011 Sep; 122(3):527-31. PubMed ID: 21664657
[TBL] [Abstract][Full Text] [Related]
39. A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer.
Gibbs DD; Pyle L; Allen M; Vaughan M; Webb A; Johnston SR; Gore ME
Br J Cancer; 2002 May; 86(9):1379-84. PubMed ID: 11986767
[TBL] [Abstract][Full Text] [Related]
40. Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study.
Giannakakis T; Ziras N; Kakolyris S; Mavroudis D; Androulakis N; Agelaki S; Parashos M; Sarra E; Dimou T; Hatzidaki D; Vlachonikolis J; Georgoulias V
Eur J Cancer; 2000 Apr; 36(6):742-7. PubMed ID: 10762746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
